Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...

AbbVie on Wednesday reported better-than-expected quarterly revenue and profit, ​fueled by demand for newer immunology drugs ...

Bimekizumab demonstrated a consistent safety profile across patients with PsA or axSpA in an integrated safety analysis, with the drug showing long-term tolerability.

The December 2025 PSA buyback scandal, involving secret grade upgrades after card buybacks, is shaking trust across the $5B sports card market. Collectors reacted strongly when the PSA grading scandal ...

Collectors reacted strongly when the PSA grading scandal of 2026 broke in December 2025. A Pokémon collector submitted around 30 identical modern cards that mostly returned as PSA 9 grades. He ...

View post: MLB Home Run Predictions Today: Best HR Prop Bets for Thursday, April 30 View post: Old Navy's Soft V-Neck Tees Are $5 to $7 and Have Over 10,000 5-Star Reviews Old Navy's Soft V-Neck Tees ...

The Los Angeles Department of Transportation has pulled public service announcement videos asking riders to refrain from pooping on city buses. The videos were part of their PSA campaign called "If ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira(R) (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk ...

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025 results, which, according to BNP Paribas, were driven by its older blockbuster ...

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising superstar Skyrizi. Despite the fall of what was once the world’s top-selling ...

AbbVie Inc. (NYSE: ABBV) reported fourth-quarter 2025 sales of $16.62 billion on Wednesday, beating the consensus of $16.42 billion. Sales increased 10% on a reported basis or 9.5% on an operational ...